Cytonet LLC’s Liver Cell Therapy May Be Effective In Stabilizing Children With Severe Urea Cycle Disorders Awaiting Liver Transplant
7/28/2014 9:01:44 AM
SAN FRANCISCO & RALEIGH-DURHAM, N.C.--(BUSINESS WIRE)--Cytonet announced today that new research on its investigational liver cell therapy (LCT) was presented on July 27, 2014 at the 2014 World Transplant Congress (WTC) in San Francisco. The presentation, titled “Clinical Outcome in Children with Urea Cycle Deficiencies after Liver Cell Therapy in Comparison to a Control Group,” demonstrates how investigational liver cell therapy may help temporarily stabilize pediatric patients with urea cycle disorders (UCD) as they await liver transplantation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by